Patient characteristics
| Clinical parameter . | Study population (n = 49) . |
|---|---|
| Sex: male/female | 27/22 |
| Age in years: median (range) | 38 (16-56) |
| Diagnosis | |
| AML CR1 | 11 |
| AML > CR1 | 2 |
| ALL CR1 | 4 |
| ALL > CR1 | 2 |
| CML CP1 | 7 |
| CLL | 2 |
| Hodgkin | 1 |
| MDS | 1 |
| Multiple myeloma | 9 |
| NHL | 9 |
| SAA | 1 |
| Risk status: SR/PR | 21/28 |
| Donor type | |
| Sib | 35 |
| MUD | 14 |
| Conditioning regimen | |
| Cy/TBI | 33 |
| Cy/TBI/ATG | 15 |
| Bu/Cy | 1 |
| Graft characteristics | |
| MNC × 108/kg | 0.09 (0.01-0.74) |
| CD34 × 106/kg | 1.68 (0.53-11.1) |
| CD3 × 105/kg | 2.0 (1.0-4.0) |
| CFU-GM × 104/kg | 19.0 (3.0-128.0) |
| Stem cell source | |
| BM | 37 |
| PB | 12 |
| EBV serology (D/R) | |
| D+/R+ | 44 |
| D−/R− | 1 |
| D−/R+ | 1 |
| D+/R− | 3 |
| Clinical parameter . | Study population (n = 49) . |
|---|---|
| Sex: male/female | 27/22 |
| Age in years: median (range) | 38 (16-56) |
| Diagnosis | |
| AML CR1 | 11 |
| AML > CR1 | 2 |
| ALL CR1 | 4 |
| ALL > CR1 | 2 |
| CML CP1 | 7 |
| CLL | 2 |
| Hodgkin | 1 |
| MDS | 1 |
| Multiple myeloma | 9 |
| NHL | 9 |
| SAA | 1 |
| Risk status: SR/PR | 21/28 |
| Donor type | |
| Sib | 35 |
| MUD | 14 |
| Conditioning regimen | |
| Cy/TBI | 33 |
| Cy/TBI/ATG | 15 |
| Bu/Cy | 1 |
| Graft characteristics | |
| MNC × 108/kg | 0.09 (0.01-0.74) |
| CD34 × 106/kg | 1.68 (0.53-11.1) |
| CD3 × 105/kg | 2.0 (1.0-4.0) |
| CFU-GM × 104/kg | 19.0 (3.0-128.0) |
| Stem cell source | |
| BM | 37 |
| PB | 12 |
| EBV serology (D/R) | |
| D+/R+ | 44 |
| D−/R− | 1 |
| D−/R+ | 1 |
| D+/R− | 3 |
AML CR1/> CR1 indicates acute myeloid leukemia first/subsequent complete remission; ALL CR1/> CR1, acute lymphoblastic leukemia first/subsequent CR; CML CP1, chronic myeloid leukemia in first chronic phase; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; SAA, severe aplastic anemia; SR/PR, standard-risk/poor-risk disease; Sib, genotypically matched sibling donor; MUD, matched unrelated donor; Cy, cyclophosphamide; TBI, total body irradiation; ATG, antithymocyte globulin; Bu, busulphan; MNC, mononuclear cells; CFU-GM, granulocyte macrophage-colony-forming units; BM, bone marrow; PB, peripheral blood; EBV, Epstein-Barr virus; D+/−, donor EBV-seropositive/-negative; R+/−, recipient EBV-seropositive/-negative.